AmerisourceBergen Shares Perspectives on SCOTUS ACA Decision
At AmerisourceBergen, we are united in creating healthier futures and believe in the accessibility and affordability of health and pharmaceutical care. In alignment with that purpose, we’re pleased with today’s Supreme Court Affordable Care Act decision which creates peace of mind for patients everywhere as necessary protections will continue, including essential bans on lifetime benefit caps and restrictions based on pre-existing conditions. In addition, today’s decision effectively preserves the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which enables a critical pathway for Biosimilar therapies to come to market. The preservation of the BPCIA pathway is a win for patient access and pharmaceutical innovation. Biosimilars play an essential role in lowering drug prices across therapeutic categories and expanding patient access to treatments.